Regatta Research & Money Management’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Regatta Research & Money Management’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$47.5K	Buy	+480	New	+$43.3K	0.04%	265

Other funds holding IHE

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return

IWS

Insight Wealth Strategies San Ramon, California $1.02B AUM 38% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

MCM

Monument Capital Management Alexandria, Virginia $497M AUM 52.58% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

CIA

Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return

Regatta Research & Money Management's IHE Position: Q2 2026 in Review

Regatta Research & Money Management opened a new position in iShares US Pharmaceuticals ETF (IHE) in Q2 2026: 480 shares worth $47.5K. The stake represents 0.04% of the portfolio and ranks #265 among its holdings.

167 funds tracked by Wall St. Rank hold IHE as of Q2 2026.

Regatta Research & Money Management held 480 shares of iShares US Pharmaceuticals ETF worth $47.5K as of Q2 2026.
iShares US Pharmaceuticals ETF was a new Regatta Research & Money Management position in Q2 2026.
iShares US Pharmaceuticals ETF made up 0.04% of Regatta Research & Money Management's portfolio in Q2 2026, its #265 holding.
167 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q2 2026.

Based on Regatta Research & Money Management's 13F filing for Q2 2026, filed 12 Aug 2026.